Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

582 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Are liquid biopsies a surrogate for tissue EGFR testing?
Goldman JW, Noor ZS, Remon J, Besse B, Rosenfeld N. Goldman JW, et al. Among authors: besse b. Ann Oncol. 2018 Jan 1;29(suppl_1):i38-i46. doi: 10.1093/annonc/mdx706. Ann Oncol. 2018. PMID: 29462257 Free article. Review.
Targeted therapies in lung cancer.
Besse B, Ropert S, Soria JC. Besse B, et al. Ann Oncol. 2007 Jul;18 Suppl 9:ix135-42. doi: 10.1093/annonc/mdm308. Ann Oncol. 2007. PMID: 17631566 Free article. Review. No abstract available.
[KRAS status versus EGFR status in lung cancer therapy].
Lacroix L, Besse B, Bidart JM, Bosq J. Lacroix L, et al. Among authors: besse b. Bull Cancer. 2009 Dec;96 Suppl:S75-83. doi: 10.1684/bdc.2009.0999. Bull Cancer. 2009. PMID: 20034873 Review. French.
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors.
Barlési F, Balleyguier C, Besse B, Bonodeau F, Brenac F, Corneloup O, Dansin E, Ferretti G, Gaubert JY, Gervais R, Lacombe C, Loundou A, Moro-Sibilot D, Planchard D, Scherpereel A, Menu Y. Barlési F, et al. Among authors: besse b. Ann Oncol. 2010 Aug;21(8):1682-1686. doi: 10.1093/annonc/mdp590. Epub 2010 Jan 11. Ann Oncol. 2010. PMID: 20064831 Free article.
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
Gauler TC, Besse B, Mauguen A, Meric JB, Gounant V, Fischer B, Overbeck TR, Krissel H, Laurent D, Tiainen M, Commo F, Soria JC, Eberhardt WEE. Gauler TC, et al. Among authors: besse b. Ann Oncol. 2012 Mar;23(3):678-687. doi: 10.1093/annonc/mdr255. Epub 2011 May 26. Ann Oncol. 2012. PMID: 21617019 Free article. Clinical Trial.
582 results